Standout Papers

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line ... 2016 2026 2019 2022 309
  1. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study (2016)
    Kazunari Murakami, Yuuichi Sakurai et al. Gut

Immediate Impact

3 from Science/Nature 76 standout
Sub-graph 1 of 20

Citing Papers

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection
2024 Standout
Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022
2024 Standout
21 intermediate papers

Works of Nobuo Funao being referenced

Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study
2017
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
2016 Standout
and 3 more

Author Peers

Author Last Decade Papers Cites
Nobuo Funao 508 398 38 214 12 609
C A Dorrian 485 275 8 144 9 563
L. Lombardo 380 251 27 100 23 637
Misako Takashima 443 178 31 129 21 579
S Lanzon-Miller 448 335 17 137 17 562
Lisa Suchower 396 185 86 143 19 599
Mahmoud M. Yousfi 439 200 16 285 16 575
C. Ó’Moráin 594 428 11 218 26 701
Byoung Hwan Lee 450 191 18 238 14 538
David Y. Graham 545 169 173 159 8 615
Mitsuhiro Mihara 509 269 16 292 17 543

All Works

Loading papers...

Rankless by CCL
2026